RxDoctor Payments Data

Mindi Fry

Nurse Practitioner · Fredericksburg, VANPI 1447560669

Payments from drug & device makers

$4,700in general payments, 2019–2025

Across 191 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$734
  • Boston Scientific$402
  • Heartflow, Inc.$344
  • AstraZeneca$306
  • Abbott$280
  • E.r. Squibb & Sons, L.L.C.$248
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,54397%
  • Education$1583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,700 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$56,465
Medicare patients
502
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$161,003
EntrestoSacubitril/Valsartan50$70,732
FarxigaDapagliflozin Propanediol22$28,027
MultaqDronedarone Hcl20$24,778
XareltoRivaroxaban19$23,719
JardianceEmpagliflozin15$21,981
Dofetilide21$6,872
Metoprolol Succinate132$2,194
Rosuvastatin Calcium146$2,122
Droxidopa13$1,300
Ranolazine ErRanolazine14$1,226
Ezetimibe45$1,219
Flecainide Acetate34$1,133
ClopidogrelClopidogrel Bisulfate47$630
Amiodarone Hcl12$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$161,003143 claims
NovartisEntresto$235$70,73250 claims
AstraZenecaFarxiga$306$28,02722 claims
Sanofi-aventis U.S. LLCMultaq$27$24,77820 claims
Johnson & JohnsonXarelto$24$23,71919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →